Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 13.31M P/E - EPS this Y - Ern Qtrly Grth -
Income -14.54M Forward P/E - EPS next Y - 50D Avg Chg -20.00%
Sales -7.53M PEG - EPS past 5Y - 200D Avg Chg -55.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -84.00%
Recommedations - Quick Ratio 0.03 Shares Outstanding 15.98M 52W Low Chg 12.00%
Insider Own 38.48% ROA -33.19% Shares Float 10.34M Beta 0.31
Inst Own 1.59% ROE -128.85% Shares Shorted/Prior 300.71K/2.55M Price 1.30
Gross Margin - Profit Margin - Avg. Volume 58,824 Target Price -
Oper. Margin 103,749.17% Earnings Date Aug 19 Volume 36,163 Change -6.47%
About Avalon GloboCare Corp.

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States. The company focuses to develop diagnostics and clinical laboratory services through ownership acquisition or license rights in precision diagnostic assets, genetic testing and clinical laboratory companies through joint ventures, and share ownership structures or distribution rights. The company was founded in 2016 and is headquartered in Freehold, New Jersey.

Avalon GloboCare Corp. News
11/21/24 Avalon GloboCare Regains Compliance with Nasdaq Continued Listing Requirements
11/18/24 Avalon GloboCare Launches “BrAce for Impact" Affiliate Marketing Program for the KetoAir Breathalyzer Device
11/15/24 Avalon GloboCare Third Quarter 2024 Earnings: US$1.82 loss per share (vs US$2.06 loss in 3Q 2023)
11/04/24 Top Premarket Decliners
10/31/24 Avalon GloboCare Appoints Dr. Charles Cavo to its Scientific Advisory Board in Support of KetoAir Sales
10/25/24 Avalon GloboCare and Qi Diagnostics Enter into Memorandum of Understanding for Proposed Co-Development of Real-Time Cannabis Breathalyzer for Detecting Potential Impaired Driving
10/25/24 EXCLUSIVE: Avalon GloboCare Inks MoU With Qi Diagnostics For Proposed Co-Development Of Real-Time Cannabis Breathalyzer
08:00 AM Avalon GloboCare Announces 1-for-15 Reverse Stock Split as Part of Nasdaq Compliance Plan
10/09/24 Avalon GloboCare to Sponsor Keto Pa-LOU-za 2024 Conference and Showcase KetoAir Breathalyzer Device
08/14/24 Avalon’s Laboratory Services MSO to Launch Sales of Proprietary FDA-Registered External Male Catheter Device
08/14/24 EXCLUSIVE: Avalon's Lab Services MSO Poised To Commercialize FDA-Registered External Male Catheter Device
07/31/24 Avalon’s Laboratory Services MSO Launches DNA Testing Kit for Predisposition to Opioid Addiction
07/18/24 Avalon GloboCare Launches Online Sales of KetoAir Breathalyzer in the U.S. at Ketoair.us
06/21/24 7 F-Rated Penny Stocks to Avoid This June
06/20/24 Avalon GloboCare Provides Update on the Launch of the KetoAir Breathalyzer at Hack Your Health by KetoCon 2024 Conference
04:00 PM Avalon GloboCare Receives Notice from Nasdaq Regarding Delayed Quarterly Report
04/22/24 Avalon GloboCare Announces Launch of U.S. Sales of KetoAir Breathalyzer at the Hack Your Health by KetoCon 2024 Conference
03/28/24 Avalon GloboCare Extends Exclusivity Agreement to Distribute KetoAir Breathalyzer Device and AI-Enabled Software in North America, South America, United Kingdom and European Union